Lineage Cell Therapeutics Share Price Today
(NASDAQ: LCTX)

Name: Lineage Cell Therapeutics Share Price Today (NASDAQ: LCTX) - Lineage Cell Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Lineage Cell Therapeutics share price is $0.52 & ₹45.22 as on 6 Mar 2025, 2.30 'hrs' IST

$0.52

▲

-0.01

(-2.55%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Lineage Cell Therapeutics share price in Dollar and Rupees. Guide to invest in Lineage Cell Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Lineage Cell Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Lineage Cell Therapeutics share price movements

Today's Low: $0.52
Today's High: $0.55
$0.52
0.0%
Downside
Day's Volatility :4.92%
Upside
4.92%
52 Weeks Low: $0.48
52 Weeks High: $1.61
$0.52
7.5%
Downside
52 Weeks Volatility :70.12%
Upside
67.7%

Lineage Cell Therapeutics (LCTX) Returns

Period	Lineage Cell Therapeutics Inc	Index (Russel 2000)
3 Months	-6.72%	0.0%
6 Months	-38.83%	0.0%
1 Year	-52.85%	0.0%
3 Years	-58.37%	-11.6%

Lineage Cell Therapeutics (LCTX) Key Statistics

in dollars & INR

Previous Close	$0.5328
Open	$0.5326
Today's High	$0.5469
Today's Low	$0.52
Market Capitalization	$116.5M
Today's Volume	$169.8K
52 Week High	$1.61
52 Week Low	$0.481
Revenue TTM	$8.7M
EBITDA	$-18.6M
Earnings Per Share (EPS)	$-0.1
Profit Margin	-230.66%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-30.5%

How to invest in Lineage Cell Therapeutics Stock (LCTX) from India?

It is very easy for Indian residents to invest directly in Lineage Cell Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Lineage Cell Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Lineage Cell Therapeutics or LCTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Lineage Cell Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Lineage Cell Therapeutics shares which would translate to 1.672 fractional shares of Lineage Cell Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Lineage Cell Therapeutics, in just a few clicks!

Returns in Lineage Cell Therapeutics (LCTX) for Indian investors in Rupees

The Lineage Cell Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Lineage Cell Therapeutics investment value today

Current value as on today

₹50,980

Returns

₹49,020

(-49.02%)

Returns from Lineage Cell Therapeutics Stock

₹53,982 (-53.98%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Lineage Cell Therapeutics (LCTX)

-35%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Lineage Cell Therapeutics Stock from India on INDmoney has decreased by -35% in the last 30 days, reflecting a downward trend in search activity.

Analyst Recommendation on Lineage Cell Therapeutics

Buy

83%Buy

16%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Lineage Cell Therapeutics(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Lineage Cell Therapeutics Stock (LCTX)

What analysts predicted

Upside of 765.38%

Target:

$4.50

Current:

$0.52

Insights on Lineage Cell Therapeutics Stock (Ticker Symbol: LCTX)

Price Movement
In the last 7 days, LCTX stock has moved down by -15.0%
Increasing Revenue
Revenue is up for the last 2 quarters, 1.40M → 3.77M (in $), with an average increase of 62.7% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -6.54M → -3.03M (in $), with an average increase of 51.7% per quarter
LCTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 113.0%
LCTX vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 105.4%
Price to Sales
ForLCTX every $1 of sales, investors are willing to pay $11.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

LCTX Lineage Cell Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.4M	↓ 20.98%
Net Income	$-46.0M	↑ 130.23%
Net Profit Margin	-3.2K%	↓ 2133.15%

	FY19	Y/Y Change
Revenue	$1.5M	↑ 4.38%
Net Income	$-11.8M	↓ 74.28%
Net Profit Margin	-800.2%	↑ 2447.68%

	FY20	Y/Y Change
Revenue	$773.0K	↓ 47.7%
Net Income	$-20.7M	↑ 74.9%
Net Profit Margin	-2.7K%	↓ 1875.74%

	FY21	Y/Y Change
Revenue	$3.9M	↑ 404.01%
Net Income	$-38.6M	↑ 86.43%
Net Profit Margin	-989.84%	↑ 1686.1%

	FY22	Y/Y Change
Revenue	$14.7M	↑ 277.39%
Net Income	$-26.4M	↓ 31.66%
Net Profit Margin	-179.24%	↑ 810.6%

	FY23	Y/Y Change
Revenue	$8.9M	↓ 39.16%
Net Income	$-21.5M	↓ 18.47%
Net Profit Margin	-240.2%	↓ 60.96%

	Q2 FY23	Q/Q Change
Revenue	$3.2M	↑ 35.16%
Net Income	$-5.2M	↑ 18.73%
Net Profit Margin	-162.14%	↑ 22.44%

	Q3 FY23	Q/Q Change
Revenue	$1.2M	↓ 61.36%
Net Income	$-7.1M	↑ 35.97%
Net Profit Margin	-570.63%	↓ 408.49%

	Q4 FY23	Q/Q Change
Revenue	$2.1M	↑ 67.58%
Net Income	$-4.8M	↓ 32.84%
Net Profit Margin	-228.69%	↑ 341.94%

	Q1 FY24	Q/Q Change
Revenue	$1.4M	↓ 30.84%
Net Income	$-6.5M	↑ 37.01%
Net Profit Margin	-453.05%	↓ 224.36%

	Q2 FY24	Q/Q Change
Revenue	$1.4M	↓ 2.49%
Net Income	$-5.8M	↓ 11.95%
Net Profit Margin	-409.09%	↑ 43.96%

	Q3 FY24	Q/Q Change
Revenue	$3.8M	↑ 168.39%
Net Income	$-3.0M	↓ 47.33%
Net Profit Margin	-80.29%	↑ 328.8%

	FY18	Y/Y Change
Profit	$1.1M	↓ 31.4%

	FY19	Y/Y Change
Profit	$1.1M	↓ 4.31%

	FY20	Y/Y Change
Profit	$388.0K	↓ 63.6%

	FY21	Y/Y Change
Profit	$2.5M	↑ 536.6%

	FY22	Y/Y Change
Profit	$14.0M	↑ 465.79%

	FY23	Y/Y Change
Profit	$8.3M	↓ 40.79%

	Q2 FY23	Q/Q Change
Profit	$3.1M	↑ 36.66%

	Q3 FY23	Q/Q Change
Profit	$1.1M	↓ 65.24%

	Q4 FY23	Q/Q Change
Profit	$1.7M	↑ 53.85%

	Q1 FY24	Q/Q Change
Profit	$1.2M	↓ 29.33%

	Q2 FY24	Q/Q Change
Profit	$1.4M	↑ 16.48%

	Q3 FY24	Q/Q Change
Profit	$3.7M	↑ 174.27%

	FY18	Y/Y Change
Operating Cash Flow	$-30.9M	↑ 1.2%
Investing Cash Flow	$11.8M	↓ 215.56%
Financing Cash Flow	$5.8M	↓ 89.58%

	FY19	Y/Y Change
Operating Cash Flow	$-31.9M	↑ 3.45%
Investing Cash Flow	$17.0M	↑ 43.51%
Financing Cash Flow	$617.0K	↓ 89.31%

	FY20	Y/Y Change
Operating Cash Flow	$-19.8M	↓ 38.17%
Investing Cash Flow	$13.0M	↓ 23.11%
Financing Cash Flow	$29.9M	↑ 4740.36%

	FY21	Y/Y Change
Operating Cash Flow	$-23.6M	↑ 19.28%
Investing Cash Flow	$9.7M	↓ 25.26%
Financing Cash Flow	$36.9M	↑ 23.66%

	FY22	Y/Y Change
Operating Cash Flow	$1.1M	↓ 104.49%
Investing Cash Flow	$-46.2M	↓ 573.67%
Financing Cash Flow	$1.6M	↓ 95.58%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-6.3M	↓ 44.24%
Investing Cash Flow	$19.2M	↑ 24.2%
Financing Cash Flow	$5.6M	↑ 562700.0%

Lineage Cell Therapeutics Technicals Summary

Sell

Neutral

Buy

Lineage Cell Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Lineage Cell Therapeutics (LCTX) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Lineage Cell Therapeutics Inc	-19.26%	-38.83%	-52.85%	-58.37%	-33.4%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Lineage Cell Therapeutics Inc	NA	NA	NA	-0.11	-0.3	-0.12	NA	0.35
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Lineage Cell Therapeutics Inc	Buy	$116.5M	-33.4%	NA	-230.66%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Organization	Lineage Cell Therapeutics
Employees	68
CEO	Mr. William Annett MBA
Industry	Health Technology

Management People of Lineage Cell Therapeutics

Name	Title
Mr. Brian M. Culley M.A., M.B.A.	CEO, President & Director
Ms. Jill Ann Howe	CFO & Principal Financial and Accounting Officer
Mr. George A. Samuel III, J.D.	General Counsel & Company Secretary
Ms. Ioana C. Hone	Director of Investor Relations
Dr. Charlotte Hubbert Ph.D.	Vice President of Corporate Development
Ms. Brandi L. Roberts CPA, M.B.A.	Consultant
Mr. William Annett MBA	President & CEO of OncoCyte Corporation
Dr. Rami Skaliter Ph.D.	Chief Executive Officer of Cell Cure Neurosciences
Ms. Alexandra Hernandez	Senior Director of Finance & Controller
Dr. Harold D. Waitz	Vice President of Regulatory Affairs & Quality Control

Important FAQs about investing in LCTX Stock from India :

What is Lineage Cell Therapeutics share price today?

Lineage Cell Therapeutics share price today stands at $0.52, Open: $0.53 ; Previous Close: $0.53 ; High: $0.55 ; Low: $0.52 ; 52 Week High: $1.61 ; 52 Week Low: $0.48.

The stock opens at $0.53, after a previous close of $0.53. The stock reached a daily high of $0.55 and a low of $0.52, with a 52-week high of $1.61 and a 52-week low of $0.48.

Can Indians buy Lineage Cell Therapeutics shares?

Yes, Indians can invest in the Lineage Cell Therapeutics (LCTX) from India.

With INDmoney, you can buy Lineage Cell Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Lineage Cell Therapeutics at zero transaction cost.

How can I buy Lineage Cell Therapeutics shares from India?

It is very easy to buy Lineage Cell Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Lineage Cell Therapeutics (LCTX) be purchased?

Yes, you can buy fractional shares of Lineage Cell Therapeutics with INDmoney app.

What are the documents required to start investing in Lineage Cell Therapeutics stocks?

To start investing in Lineage Cell Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.